vs
Side-by-side financial comparison of Element Solutions Inc (ESI) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
Element Solutions Inc is the larger business by last-quarter revenue ($840.0M vs $598.7M, roughly 1.4× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 6.7%, a 34.2% gap on every dollar of revenue. On growth, Element Solutions Inc posted the faster year-over-year revenue change (41.0% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-74.2M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 17.1%).
Element Solutions Inc is an American specialty chemicals production corporation listed on the New York Stock Exchange.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ESI vs EXEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $840.0M | $598.7M |
| Net Profit | $56.0M | $244.5M |
| Gross Margin | 38.4% | 95.6% |
| Operating Margin | 13.3% | 39.3% |
| Net Margin | 6.7% | 40.8% |
| Revenue YoY | 41.0% | 5.6% |
| Net Profit YoY | -42.9% | 74.8% |
| EPS (diluted) | $0.23 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $840.0M | $598.7M | ||
| Q4 25 | $676.2M | $597.8M | ||
| Q3 25 | $656.1M | $568.3M | ||
| Q2 25 | $625.2M | $555.4M | ||
| Q1 25 | $593.7M | $566.8M | ||
| Q4 24 | $624.2M | — | ||
| Q3 24 | $645.0M | $539.5M | ||
| Q2 24 | $612.7M | $637.2M |
| Q1 26 | $56.0M | $244.5M | ||
| Q4 25 | $6.2M | $193.6M | ||
| Q3 25 | $39.3M | $184.8M | ||
| Q2 25 | $47.4M | $159.6M | ||
| Q1 25 | $98.0M | $139.9M | ||
| Q4 24 | $54.7M | — | ||
| Q3 24 | $40.3M | $118.0M | ||
| Q2 24 | $93.2M | $226.1M |
| Q1 26 | 38.4% | 95.6% | ||
| Q4 25 | 40.9% | 96.9% | ||
| Q3 25 | 42.2% | 96.6% | ||
| Q2 25 | 42.6% | 96.5% | ||
| Q1 25 | 42.2% | 96.5% | ||
| Q4 24 | 41.0% | — | ||
| Q3 24 | 41.5% | 96.8% | ||
| Q2 24 | 43.6% | 97.2% |
| Q1 26 | 13.3% | 39.3% | ||
| Q4 25 | 10.3% | 39.6% | ||
| Q3 25 | 15.4% | 37.6% | ||
| Q2 25 | 15.1% | 33.6% | ||
| Q1 25 | 13.0% | 28.8% | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | 14.7% | 25.2% | ||
| Q2 24 | 15.7% | 43.3% |
| Q1 26 | 6.7% | 40.8% | ||
| Q4 25 | 0.9% | 32.4% | ||
| Q3 25 | 6.0% | 32.5% | ||
| Q2 25 | 7.6% | 28.7% | ||
| Q1 25 | 16.5% | 24.7% | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 6.2% | 21.9% | ||
| Q2 24 | 15.2% | 35.5% |
| Q1 26 | $0.23 | $0.89 | ||
| Q4 25 | $0.03 | $0.69 | ||
| Q3 25 | $0.16 | $0.65 | ||
| Q2 25 | $0.20 | $0.55 | ||
| Q1 25 | $0.40 | $0.47 | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.17 | $0.40 | ||
| Q2 24 | $0.39 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.3M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $2.2B |
| Total Assets | $5.7B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.3M | $1.1B | ||
| Q4 25 | $626.5M | $988.5M | ||
| Q3 25 | $594.3M | $791.1M | ||
| Q2 25 | $529.9M | $1.0B | ||
| Q1 25 | $499.2M | $1.1B | ||
| Q4 24 | $359.4M | — | ||
| Q3 24 | $376.0M | $1.2B | ||
| Q2 24 | $309.3M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — |
| Q1 26 | $2.7B | $2.2B | ||
| Q4 25 | $2.7B | $2.2B | ||
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.6B | $2.1B | ||
| Q1 25 | $2.5B | $2.2B | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | $2.3B | ||
| Q2 24 | $2.4B | $2.1B |
| Q1 26 | $5.7B | $2.8B | ||
| Q4 25 | $5.1B | $2.8B | ||
| Q3 25 | $5.0B | $2.7B | ||
| Q2 25 | $5.0B | $2.8B | ||
| Q1 25 | $4.8B | $2.9B | ||
| Q4 24 | $4.9B | — | ||
| Q3 24 | $5.1B | $3.0B | ||
| Q2 24 | $5.0B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.81× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $333.5M |
| Free Cash FlowOCF − Capex | $-74.2M | $332.4M |
| FCF MarginFCF / Revenue | -8.8% | 55.5% |
| Capex IntensityCapex / Revenue | 3.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | — | $290.3M | ||
| Q3 25 | $100.1M | $49.0M | ||
| Q2 25 | — | $211.4M | ||
| Q1 25 | $26.0M | $240.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $98.5M | $271.3M | ||
| Q2 24 | — | $119.5M |
| Q1 26 | $-74.2M | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | $83.6M | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | $15.0M | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $85.9M | $263.1M | ||
| Q2 24 | — | $113.0M |
| Q1 26 | -8.8% | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | 12.7% | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | 2.5% | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.3% | 48.8% | ||
| Q2 24 | — | 17.7% |
| Q1 26 | 3.0% | 0.2% | ||
| Q4 25 | 2.5% | 0.2% | ||
| Q3 25 | 2.5% | 0.5% | ||
| Q2 25 | 2.8% | 0.5% | ||
| Q1 25 | 1.9% | 0.7% | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 2.0% | 1.5% | ||
| Q2 24 | 2.4% | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | 2.55× | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | 0.27× | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.44× | 2.30× | ||
| Q2 24 | — | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESI
| Electronics ex-Metals | $377.8M | 45% |
| Pass-through Metals | $255.7M | 30% |
| Other | $206.5M | 25% |
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
